



E-ISSN: 2616-3470

P-ISSN: 2616-3462

© Surgery Science

[www.surgeryscience.com](http://www.surgeryscience.com)

2020; 4(4): 278-280

Received: 15-02-2020

Accepted: 12-04-2020

**Dr. Amith Kiran B**

Professor, Department of General  
Surgery, Srinivas Institute of  
Medical Sciences, Mangalore,  
Karnataka, India

## A study on cardiac myxoma

**Dr. Amith Kiran B**

**DOI:** <https://doi.org/10.33545/surgery.2020.v4.i4e.571>

### Abstract

Cardiac myxomas represent the most common primary cardiac tumours, with an estimated incidence of 0.5 per million individuals annually. It is considered as a benign neoplasm. Although it can occur in almost any age, usually patient age ranges from 30-60 years, with a female predilection. Clinically myxomas may present with a variety of symptoms such as obstructive cardiac, embolic and constitutional. Dyspnoea, thoracic pain, cough, dizziness and heart failure.

**Keywords:** Myxoma, cardiac tumours, pain, cough, dizziness and heart failure

### Introduction

A myxoma is a rare benign tumor of the heart. Myxomas are the most common primary cardiac tumor in adults, and are most commonly found within the left atrium. Myxomas may also develop in the other heart chambers. The tumor is derived from multipotent mesenchymal cells. Although a myxoma is not malignant with risk of metastasis,<sup>[4]</sup> complications are common. Untreated, a myxoma can lead to an embolism (tumor cells breaking off and traveling with the bloodstream). Myxoma fragments can move to the brain, eye, or limbs.

If the tumor continues to enlarge inside the heart, it can block blood flow through the mitral valve and cause symptoms of mitral stenosis or mitral regurgitation. This may require emergency surgery to prevent sudden death<sup>[7]</sup>.

Cardiac myxomas represent the most common primary cardiac tumours, with an estimated incidence of 0.5 per million individuals annually<sup>[1]</sup>. It is considered as a benign neoplasm. Although it can occur in almost any age, usually patient age ranges from 30-60 years, with a female predilection<sup>[2]</sup>. Clinically myxomas may present with a variety of symptoms such as obstructive cardiac, embolic and constitutional<sup>[3]</sup>. Dyspnoea, thoracic pain, cough, dizziness and heart failure are the usual obstructive cardiac signs and this is due to tumour prolapse into the mitral orifice<sup>[3]</sup>.

Peripheral or pulmonary emboli or stroke are the embolic manifestations<sup>[4]</sup>. Arthralgia, myalgia, fever, rash, weight loss, cachexia, fatigue, Reynaud's phenomenon are the constitutional symptoms and they are related to the production of IL-6 by tumor cells<sup>[3,5]</sup>.

Over 72% of primary cardiac tumours are benign and myxomas account for 80% of all cardiac tumours<sup>[6]</sup>. Myxomas are composed of cells, primitive capillaries, and foci of extramedullary haematopoiesis within a myxoid matrix of acid mucopolysaccharide. They are considered to arise from multipotential mesenchymal cells capable of differentiating into various types of cells, a view supported by the finding of bone and bone marrow tissue in myxomas<sup>[7]</sup>. Although therapy as well as the antemortem diagnosis of this pathological entity seems to be very successful, the underlying cause still remains unclear.

The interleukin-6 and endothelial growth factor have been identified as markers of these tumours<sup>[8,9]</sup>. About 10% of cardiac myxoma is familial and almost all are related to the Swiss-Carney syndrome. This is a multiple neoplasia and lentiginosis syndrome.

The sporadic tumours that represent the majority of this pathology and these tumour lack a clearly defined pathological cause<sup>[10]</sup>. Myxoma occur in older adults and are two to three times more common in women than in men<sup>[11]</sup>. They are rare in children and have not yet been described in infants<sup>[12]</sup>.

**Corresponding Author:**

**Dr. Amith Kiran B**

Professor, Department of General  
Surgery, Srinivas Institute of  
Medical Sciences, Mangalore,  
Karnataka, India

**Aims and Objectives**

**To study the cardiac myxomas**

**Materials and Methods**


This study was done in the Department of Surgery at Srinivas Institute of medical Sciences, mangalore. This study was done from Feb 2018 to March 2019. Twenty one cases was the sample size of the study. The signs and the symptoms were noted. All tumours were histologically proven to be cardiac myxoma. Details data were collected from the operation data base and the patient records. Transthoracic echocardiography was the diagnostic tool in all cases. The historical longitudinal study was performed. All patients underwent operation soon after the diagnosis of a myxoma was made. Cardiopulmonary

bypass was established with aortic and bicaval canulations. Routine St Thomas II root cardioplegia was used in all cases. Right atrial approach was done in all cases. Complete tumour excision was performed in all cases.

**Results**

**Table 1: Age Distribution**

15-20 years	01
21-30 years	11
31-40 years	04
41-50 years	02
50-60 years	03



**Fig 2: Sex Distribution**

**Table 2: Signs and symptoms**

<b>Dyspnoea on Exertion</b>	<b>15/21 patients</b>
Palpitations alone or with Dyspnoea on Exertion / Palpitation / Syncope / CV Accidents	08
Dizziness / Syncope	03
CV Accidents	3
Constitutional Symptoms alone or with Dyspnoea on Exertion / Palpitation / Syncope / CV accidents	07

**Diagnosis was confirmed in 100 percent by transthoracic echocardiography**

**Table 3: Location**

Right Atrium	01
Left Atrium	18
Right Ventricle	01
Tricuspid Valve Annulus	01

**Discussion**

The presenting clinical feature of cardiac myxoma depend on it location, size, and mobility inside the heart. Symptoms range from non-specific to constitutional to sudden cardiac death. Myxoma are asymptomatic and are discovered as an incidental finding in about 20% cases. Most patients present with one or combination of symptom of exertional dyspnoea, palpitation, embolism, and constitutional symptoms. Cardiac myxoma patients, two third of patients has symptoms of heart failure or syncope and rest one third of them presented with systemic embolization [5, 13]. Echocardiography is the investigation of choice and it gives diagnosis with fair degree of accuracy. It can fairly define tumour location, size, shape, attachment, and mobility and presence of the tumour multiplicity in other chambers of heart. It is non-invasive and avoids the risk of

tumour embolization. The transoesophageal echocardiography approach is particularly helpful in detecting the site of insertion and morphological features of atrial and ventricular myxomas. [14] Transthoracic and transoesophageal echocardiography has sensitivity of 95% and 100% respectively for the diagnosis of myxoma [15].

**Conclusion**

Diagnosis was confirmed in 100 percent by transthoracic echocardiography. Prompt diagnosis and treatment is the need of the hour for this pathology. Precious lives can be saved and this paper is intended to be of great help to the budding surgeons and they should always have this in the differential diagnosis.

**References**

1. Odim J, Reehal V, Laks H, *et al.* Surgical pathology of cardiac tumors. Two decades at an urban institution. *Cardiovasc Pathol* 2003;12(5):267-270.
2. Siminelakis S, Kakourou A, Batistatou A, *et al.* Thirteen years follow-up of heart myxoma operated patients: what is the appropriate surgical technique? *J Thorac Dis* 2014;6(1):S32-38.
3. Centofanti P, Rosa E, Deorsola L, *et al.* Primary cardiac tumors: early and late results of surgical treatment in 91

- patients. *Ann Thorac Surg* 1999;68(4):1236-1241.
4. Vogel B, Thomas D, Mereles D, *et al.* Systemic embolization and myocardial infarction due to clinically unrecognized left atrial myxoma. *Case Rep Med Article ID* 159024, 2011, 3.
  5. Pinede L, Duhaut P, Loire R. Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases. *Medicine (Baltimore)* 2001;80(3):159-172.
  6. Lone RA, Ahanger AG, Singh S, *et al.* Atrial myxoma: trends in management. *Int J Health Sci (Qassim)* 2008;2(2):141-151.
  7. Keeling IM, Oberwalder P, Anneli-Monti M, *et al.* Cardiac myxomas: 24 years of experience in 49 patients. *Eur J Cardiothorac Surgery* 2002;22(6):971-977.
  8. Arciniegas E, Hakimi M, Farooki ZQ, *et al.* Primary cardiac tumors in children. *J Thorac Cardiovasc Surg* 1980;79:582-591.
  9. Obeid AI, Marvasti M, Parker F, *et al.* Comparison of transthoracic and transesophageal echocardiography in diagnosis of left atrial myxomas. *Am J Cardiol* 1989;63(13):1006-1008.
  10. Crafoord C. Discussion of Glover RP. Late results of mitral commissurotomy. In: Lam CR, ed. *Henry Ford hospital international symposium on cardiovascular surgery: studies in physiology, diagnosis and techniques: proceedings of the symposium.* Philadelphia, PA: WB Saunders 1955;202-211.
  11. McAllister HA. Primary tumours of the heart and pericardium. *Pathol Annu* 1979;14(2):325-355.
  12. Herbst M, Wattjes MP, Urbach H, *et al.* Cerebral embolism from left atrial myxoma leading to cerebral and retinal aneurysms: a case report. *American Journal of Neuroradiology* 2005;26(3):666-669.
  13. Zahrani IMA, Alraqtan A, Rezk A, *et al.* Atrial myxoma related myocardial infarction: case report and review of the literature. *Journal of the Saudi Heart Association* 2014;26(3):166-169.
  14. Mendoza CE, Rosado MF, Bernal L. The role of interleukin-6 in cases of cardiac myxoma: clinical features, immunologic abnormalities, and a possible role in recurrence. *Tex Heart Inst J* 2001;28(1):3-7.
  15. Bennet KR, Gu JW, Adair TH, *et al.* Elevated plasma concentration of vascular endothelial growth factor in cardiac myxoma. *J Thorac Cardiovasc Surg* 2001;122:193-194.